Advertisement

International Journal of Clinical Pharmacy

, Volume 38, Issue 4, pp 749–751 | Cite as

Continuous intravenous infusion of enfuvirtide in a patient with a multidrug-resistant HIV strain

  • Robert W. NeijzenEmail author
  • Erik M. Van Maarseveen
  • Andy I. M. Hoepelman
  • Annemarie M. J. Wensing
  • Stefano Bonora
  • Antonio D’Avolio
  • Tania Mudrikova
Case Report

Abstract

Case description To evaluate whether continuous intravenous (i.v.) administration of enfuvirtide (T20) could be a suitable alternative to subcutaneous (s.c.) administration of T20 in a patient with extensively drug-resistant HIV experiencing difficulties administering T20 subcutaneously. T20 was administered to a patient through 100 mL cassettes once daily via a CADD. Plasma samples were drawn and the pharmacokinetic profile compared to that of s.c. twice daily administration of T20. Also, viral replication and CD4+ count were monitored over a period of 9 months for this study. Continuous i.v. administration of T20 resulted in significantly higher T20 plasma levels compared to s.c. administration, continued viral suppression, a rise in CD4+ count and strong patient preference over s.c. administration. Conclusion This method of T20 administration may be a suitable alternative for selected patients who are not able to tolerate it when given subcutaneously. It may even be considered a priori in selected patients with extensive viral resistance who are unable or unwilling to inject T20 subcutaneously.

Keywords

AIDS Continuous intravenous therapy Enfuvirtide HIV Resistance 

Notes

Funding

None.

Conflicts of interest

None were declared.

References

  1. 1.
    Oldfield V, Keating GM, Plosker G. Enfuvirtide: a review of its use in the management of HIV infection. Drugs. 2005;65:1139–60.CrossRefPubMedGoogle Scholar
  2. 2.
    Lalezari JP, Henry K, O’Hearn M, Montaner JSG, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175–85.CrossRefPubMedGoogle Scholar
  3. 3.
    Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186–95.CrossRefPubMedGoogle Scholar
  4. 4.
    Zhang XP, Nieforth K, Lang JM, Rouzier-Panis R, Reynes J, Dorr A, et al. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther. 2002;72:10–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Mohanty U, Dixit NM. Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor. J Theor Biol. 2008;251:541–51.CrossRefPubMedGoogle Scholar
  6. 6.
    D’Avolio A, Sciandra M, de Requena DG, Ibañez A, Bonora S, Di Perri G. An improved HPLC fluorimetric method for the determination of T20 plasma levels in HIV-infected patients. Ther Drug Monit. 2006;28:110–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, et al. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother. 2011;66:2099–106.CrossRefPubMedGoogle Scholar
  8. 8.
    de Requena DG, Bonora S, Castagna A, Hasson H, Marucco DA, D’Avolio A, et al. Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. J Antimicrob Chemother. 2008;62:384–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Korsrud GO, Boison JO, Papich MG, Yates WD, MacNeil JD, Janzen ED, et al. Depletion of intramuscularly and subcutaneously injected procaine penicillin G from tissues and plasma of yearling beef steers. Can J Vet Res. 1993;57:223–30.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  • Robert W. Neijzen
    • 1
    Email author
  • Erik M. Van Maarseveen
    • 1
  • Andy I. M. Hoepelman
    • 2
  • Annemarie M. J. Wensing
    • 3
  • Stefano Bonora
    • 4
  • Antonio D’Avolio
    • 4
  • Tania Mudrikova
    • 2
  1. 1.Department of Clinical PharmacyUniversity Medical Center UtrechtUtrechtThe Netherlands
  2. 2.Department of Internal Medicine and Infectious DiseasesUniversity Medical Center UtrechtUtrechtThe Netherlands
  3. 3.Department of Medical Microbiology, VirologyUniversity Medical Center UtrechtUtrechtThe Netherlands
  4. 4.Unit of Infectious Diseases, Department of Medical SciencesUniversity of TorinoTurinItaly

Personalised recommendations